Lorem ipsum dolor sit amet consectetur elit
Lorem ipsum dolor sit amet consectetur elit
Lorem ipsum dolor sit amet consectetur elit
Policy changes, competitive breakthroughs, technology innovations—most leaders see these coming too late. I bring my economics, strategy, and foreign intelligence background to help executives forecast the next bet that blindside their competitors.
For pharmaceutical clients, I make sense of economic and industry trends, explain their implications for business revenues and growth, and develop practical strategies to respond.
I develop innovative, data-driven thought leadership to help set strategic agendas within organizations and in public.
I leverage subject-matter expertise and apply economic analysis tools and techniques to generate evidence that helps the CEO office understand the implications of future and past decisions.
I undertake systematic assessments of the positive and negative effects of proposed and existing regulations, and of non-regulatory alternatives, to address the pharmaceutical/public policy issues at hand.
I leverage business-case best practices to help the CEO office build convincing, evidence-based business cases for investment, infrastructure, and public-policy proposals.
I analyze therapy areas end to end—mapping the science, standard of care, pipeline, guideline shifts, and competitor moves. I quantify patient flow, unmet need, and access headroom, and deliver market models, preparing you to make a decision.
Delivering business value from any transformation program requires significant focus, an appropriate strategy, and understanding of where your saboteurs reside.
I help define the value hypothesis, unit economics, and decision rights. Incentives and reviews align to adoption and business results.
Together, we will select three to five domains that matter for profit, speed, or risk. Write domain charters with target metrics, scale unit, and dependencies. Kill the rest.
I will help map the "point of departure" and "point of arrival" for each domain. Redesign work with AI at the core, not as a layer. Produce new workflows, controls, and handoffs that can scale. You wouldn't remodel your bathroom while the plumbing is crap, would you?
I'll help stand up a small transformation team that enables business-owned solution teams. Run the business and change the business in parallel.
Many U.S. biotech firms are indeed in need of a turnaround in 2025, driven by cash shortages, market instability, and regulatory uncertainty. Yet the sector is still innovating and growing in select areas. Firms prepared to refocus on fundamentals and efficiency are well-positioned to rebound when industry conditions improve.
I partner with former industry operators to quickly install clear decision rights, an interim control tower, and board-ready reporting. Use a CRO-caliber playbook to steady leadership focus and restore stakeholder confidence
I provide hands-on leadership support to control costs through working capital optimization, capital expenditure management, workforce rebalancing, triage vendors, optimize physical structures and their operations.
Together we will build a 13-week cash forecast, manage daily liquidity, and renegotiate terms with creditors and suppliers. Pair it with a restructuring-ready plan and a tight communications cadence.
Many U.S. biotech firms are indeed in need of a turnaround in 2025, driven by cash shortages, market instability, and regulatory uncertainty. Yet the sector is still innovating and growing in select areas. Firms prepared to refocus on fundamentals and efficiency are well-positioned to rebound when industry conditions improve.
I partner with former industry operators to quickly install clear decision rights, an interim control tower, and board-ready reporting. Use a CRO-caliber playbook to steady leadership focus and restore stakeholder confidence
I provide hands-on leadership support to control costs through working capital optimization, capital expenditure management, workforce rebalancing, triage vendors, optimize physical structures and their operations.
Together we will build a 13-week cash forecast, manage daily liquidity, and renegotiate terms with creditors and suppliers. Pair it with a restructuring-ready plan and a tight communications cadence.
Empirical research demonstrates that CEO and executive team composition significantly impacts firm performance. Developing a comprehensive behavioral profile of the executive team prior to PE/VC investment helps ensure your capital is backed by leadership equipped for success. This engagement requires a multi-hour in-person activity.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat.
Julien's deep understanding of the pharmaceutical landscape ensures impactful strategies.
Julien crafts bespoke strategies that align perfectly with your business objectives.
Leverage Julien's insights to navigate challenges and seize opportunities in the market.
Neglecting behavioral factors—such as attitudes, mindsets, resistance to change, and leadership role-modeling—can result in transformation failure, regardless of how well-designed the new processes or structures are. I am trained to profile your people to identify risks and prepare a mitigation plan.
To be launched soon… My notes on strategy, business, and life sciences industry from the the lens of a former intelligence professional.
